Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.

Oncol Lett. 2019 Jun;17(6):4891-4900. doi: 10.3892/ol.2019.10153. Epub 2019 Mar 15.

2.

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.

Krefting F, Basara N, Schütte W, Späth-Schwalbe E, Alt J, Thiel S, Kimmich M, Fischer JR, Kurz S, Griesinger F, Christoph DC.

Oncol Res Treat. 2019;42(5):243-255. doi: 10.1159/000499321. Epub 2019 Apr 17.

PMID:
30995666
3.

[Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].

Reinmuth N, Bitzer M, Deschler-Baier B, Fischer JR, Kuon J, Leipe J, Rawluk J, Schulz C, Heußel CP, Schultheiß M.

Dtsch Med Wochenschr. 2019 Mar;144(5):346-353. doi: 10.1055/a-0739-8194. Epub 2019 Jan 30. German.

PMID:
30699440
4.

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.

Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A.

Int J Cancer. 2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19.

PMID:
30653256
5.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.

PMID:
30383906
6.

Liposomal bupivacaine efficacy for postoperative pain following posterior vaginal surgery: a randomized, double-blind, placebo-controlled trial.

Jones CL, Gruber DD, Fischer JR, Leonard K, Hernandez SL.

Am J Obstet Gynecol. 2018 Nov;219(5):500.e1-500.e8. doi: 10.1016/j.ajog.2018.09.029. Epub 2018 Sep 28.

PMID:
30273586
7.

Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.

Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A.

Int J Cancer. 2019 Jan 1;144(1):190-199. doi: 10.1002/ijc.31893. Epub 2018 Oct 30.

PMID:
30255938
8.

ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.

Med Oncol. 2018 Jun 15;35(7):106. doi: 10.1007/s12032-018-1169-5.

PMID:
29905882
9.

Simultaneous Multiplexed Imaging of mRNA and Proteins with Subcellular Resolution in Breast Cancer Tissue Samples by Mass Cytometry.

Schulz D, Zanotelli VRT, Fischer JR, Schapiro D, Engler S, Lun XK, Jackson HW, Bodenmiller B.

Cell Syst. 2018 Apr 25;6(4):531. doi: 10.1016/j.cels.2018.04.004. No abstract available.

10.

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M.

Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24.

11.

Simultaneous Multiplexed Imaging of mRNA and Proteins with Subcellular Resolution in Breast Cancer Tissue Samples by Mass Cytometry.

Schulz D, Zanotelli VRT, Fischer JR, Schapiro D, Engler S, Lun XK, Jackson HW, Bodenmiller B.

Cell Syst. 2018 Jan 24;6(1):25-36.e5. doi: 10.1016/j.cels.2017.12.001. Epub 2017 Dec 27. Erratum in: Cell Syst. 2018 Apr 25;6(4):531.

12.

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA.

Ann Oncol. 2017 Dec 1;28(12):3028-3036. doi: 10.1093/annonc/mdx628.

13.

histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data.

Schapiro D, Jackson HW, Raghuraman S, Fischer JR, Zanotelli VRT, Schulz D, Giesen C, Catena R, Varga Z, Bodenmiller B.

Nat Methods. 2017 Sep;14(9):873-876. doi: 10.1038/nmeth.4391. Epub 2017 Aug 7.

14.

Detection of Wellfleet Bay Virus Antibodies in Sea Birds of the Northeastern USA.

Ballard JR, Mickley R, Brown JD, Hill NJ, Runstadler JA, Clark DE, Ellis JC, Mead DG, Fischer JR.

J Wildl Dis. 2017 Oct;53(4):875-879. doi: 10.7589/2016-10-237. Epub 2017 Jun 22.

PMID:
28640712
15.

Green Journal Update: reVITALize Definitions and Introducing a More Responsive Website.

Fischer JR, Chescheir NC.

Obstet Gynecol. 2017 Apr;129(4):601-602. doi: 10.1097/AOG.0000000000001960. No abstract available.

PMID:
28277369
16.

PREVALENCE AND DISTRIBUTION OF WELLFLEET BAY VIRUS EXPOSURE IN THE COMMON EIDER (SOMATERIA MOLLISSIMA).

Ballard JR, Mickley R, Gibbs SE, Dwyer C, Soos C, Harms NJ, Gilchrist HG, Hall JS, Franson JC, Milton GR, Parsons G, Allen B, Giroux JF, Lair S, Mead DG, Fischer JR.

J Wildl Dis. 2017 Jan;53(1):81-90. doi: 10.7589/2016-01-019. Epub 2016 Oct 20.

PMID:
27763829
17.

Aquatic fate of a double-stranded RNA in a sediment---water system following an over-water application.

Fischer JR, Zapata F, Dubelman S, Mueller GM, Uffman JP, Jiang C, Jensen PD, Levine SL.

Environ Toxicol Chem. 2017 Mar;36(3):727-734. doi: 10.1002/etc.3585. Epub 2016 Sep 19.

PMID:
27530554
18.

Cognition Effects of Low-Grade Hypoxia.

Pilmanis AA, Balldin UI, Fischer JR.

Aerosp Med Hum Perform. 2016 Jul;87(7):596-603. doi: 10.3357/AMHP.4558.2016.

PMID:
27503038
19.

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U.

Ann Oncol. 2016 Oct;27(10):1895-902. doi: 10.1093/annonc/mdw290. Epub 2016 Aug 8.

PMID:
27502710
20.

Characterizing a novel and sensitive method to measure dsRNA in soil.

Fischer JR, Zapata F, Dubelman S, Mueller GM, Jensen PD, Levine SL.

Chemosphere. 2016 Oct;161:319-324. doi: 10.1016/j.chemosphere.2016.07.014. Epub 2016 Jul 19.

PMID:
27441991
21.

Sacral Neuromodulation for the Treatment of Persistent Genital Arousal Disorder.

Jones CL, Fischer JR, Hernandez SL.

Obstet Gynecol. 2016 Aug;128(2):321-3. doi: 10.1097/AOG.0000000000001452.

PMID:
27399995
22.

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC.

Clin Lung Cancer. 2016 May;17(3):232-236.e1. doi: 10.1016/j.cllc.2016.03.003. Epub 2016 Mar 17.

23.

MORTALITY OF SELECTED AVIAN ORDERS SUBMITTED TO A WILDLIFE DIAGNOSTIC LABORATORY (SOUTHEASTERN COOPERATIVE WILDLIFE DISEASE STUDY, USA): A 36-YEAR RETROSPECTIVE ANALYSIS.

González-Astudillo V, Hernandez SM, Yabsley MJ, Mead DG, Keel KM, Munk BA, Fischer JR, Ruder MG, Brown JD, Peters VE, Nemeth NM.

J Wildl Dis. 2016 Jul;52(3):441-58. doi: 10.7589/2015-05-117. Epub 2016 May 17.

PMID:
27187034
24.

G Protection When Adding Pressurized Sleeves and Gloves to a Representative G-Suit Ensemble.

Morgan TR, Balldin U, Fischer JR.

Aerosp Med Hum Perform. 2016 May;87(5):464-9. doi: 10.3357/AMHP.4292.2016.

PMID:
27099085
25.

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.

Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C.

Lung Cancer. 2015 Dec;90(3):397-404. doi: 10.1016/j.lungcan.2015.11.007. Epub 2015 Nov 7.

PMID:
26791798
26.

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators.

J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.

27.

Just Do It!: Routine Cystoscopy Should Be Done at the Time of Gynecologic Surgery.

Fischer JR.

Obstet Gynecol. 2015 Dec;126(6):1136-7. doi: 10.1097/AOG.0000000000001169. No abstract available.

PMID:
26551190
28.

Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?

Graeter TP, Sebastian B, Bischof M, Kugler G, Fischer JR, Schneider T.

Thorac Cardiovasc Surg. 2016 Sep;64(6):501-6. doi: 10.1055/s-0035-1562940. Epub 2015 Aug 31.

PMID:
26322832
29.

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.

Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, Syrigos KN, Shen L, Chadjaa M, Wolf M.

J Thorac Oncol. 2015 Aug;10(8):1221-8. doi: 10.1097/JTO.0000000000000588.

30.

EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study.

Schuette W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Mezger J, Schumann C, Serke M, Zaun S, Dietel M, Thomas M.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1254-61. doi: 10.1158/1055-9965.EPI-14-1149. Epub 2015 Jun 12.

31.

Complications in CT-Guided, Semi-Automatic Coaxial Core Biopsy of Potentially Malignant Pulmonary Lesions.

Schulze R, Seebacher G, Enderes B, Kugler G, Fischer JR, Graeter TP.

Rofo. 2015 Aug;187(8):697-702. doi: 10.1055/s-0034-1399648. Epub 2015 Jun 10.

32.

What is new in the use of mesh in vaginal surgery? Best articles from the past year.

Fischer JR.

Obstet Gynecol. 2015 Apr;125(4):977-8. doi: 10.1097/AOG.0000000000000775. Review.

PMID:
25751224
33.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators.

Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18.

34.

Apparent increase of reported hemorrhagic disease in the midwestern and northeastern USA.

Stallknecht DE, Allison AB, Park AW, Phillips JE, Goekjian VH, Nettles VF, Fischer JR.

J Wildl Dis. 2015 Apr;51(2):348-61. doi: 10.7589/2013-12-330. Epub 2015 Jan 14.

PMID:
25588003
35.

Glycosaminoglycan binding by Borrelia burgdorferi adhesin BBK32 specifically and uniquely promotes joint colonization.

Lin YP, Chen Q, Ritchie JA, Dufour NP, Fischer JR, Coburn J, Leong JM.

Cell Microbiol. 2015 Jun;17(6):860-75. doi: 10.1111/cmi.12407. Epub 2015 Jan 24.

36.

Unexpected lymph node disease in resections for pulmonary metastases.

Seebacher G, Decker S, Fischer JR, Held M, Schäfers HJ, Graeter TP.

Ann Thorac Surg. 2015 Jan;99(1):231-6. doi: 10.1016/j.athoracsur.2014.08.038. Epub 2014 Nov 20.

PMID:
25440271
37.

[Infiltration of the superior vena cava in NSCLC: results of surgical intervention].

Windisch T, Fischer JR, Vega A, Decker S, Held M, Graeter TP.

Pneumologie. 2015 Jan;69(1):23-9. doi: 10.1055/s-0034-1390806. Epub 2014 Nov 6. German.

38.

Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.

Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium.

Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17.

39.

The impact of health care technology on medication safety.

Fischer JR.

S D Med. 2014 Jul;67(7):279-80. No abstract available.

PMID:
25076683
40.

Experimental feeding of Hydrilla verticillata colonized by stigonematales cyanobacteria induces vacuolar myelinopathy in painted turtles (Chrysemys picta).

Mercurio AD, Hernandez SM, Maerz JC, Yabsley MJ, Ellis AE, Coleman AL, Shelnutt LM, Fischer JR, Wilde SB.

PLoS One. 2014 Apr 2;9(4):e93295. doi: 10.1371/journal.pone.0093295. eCollection 2014.

41.

Characterizing lentic freshwater fish assemblages using multiple sampling methods.

Fischer JR, Quist MC.

Environ Monit Assess. 2014 Jul;186(7):4461-74. doi: 10.1007/s10661-014-3711-z. Epub 2014 Mar 18. Erratum in: Environ Monit Assess. 2014 Jul;186(7):4475-7.

PMID:
24638937
42.

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.

Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M.

Lung Cancer. 2014 Apr;84(1):62-6. doi: 10.1016/j.lungcan.2014.01.024. Epub 2014 Feb 3.

PMID:
24560332
43.

Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer.

Kreuter M, Vansteenkiste J, Herth FJ, Fischer JR, Eberhardt W, Zuna I, Reinmuth N, Griesinger F, Thomas M; TREAT investigators.

Respiration. 2014;87(3):204-10. doi: 10.1159/000355361. Epub 2013 Oct 30.

44.

Surveillance of Wildlife Diseases: Lessons from the West Nile Virus Outbreak.

McNamara TS, McLean RG, Saito EK, Wolfe PL, Gillin CM, Fischer JR, Ellis JC, French R, Martin PP, Schuler KL, McRuer D, Clark EE, Hines MK, Marsh C, Szewczyk V, Sladky K, Yon L, Hannant D, Siemer WF.

Microbiol Spectr. 2013 Oct;1(1). doi: 10.1128/microbiolspec.OH-0014-2012.

PMID:
26184818
45.

The epizootiology of anatid herpesvirus 1 infection in free-flying waterfowl: a comparison of latent and active infections among native waterfowl, captive-reared released ducks, and peridomestic or feral ducks.

Keel MK, Stallknecht D, Cobb D, Cunningham M, Goekjian V, Gordon-Akhvlediani S, Fischer JR.

J Wildl Dis. 2013 Jul;49(3):486-91. doi: 10.7589/2012-10-250.

PMID:
23778596
46.

What is new in obstetric anal sphincter injuries?: Best articles from the past year.

Fischer JR.

Obstet Gynecol. 2013 Jul;122(1):154-5. doi: 10.1097/AOG.0b013e31829769a6.

PMID:
23743463
47.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.

J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.

48.

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.

Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, Reck M, Fischer JR.

Lung Cancer. 2013 Jun;80(3):319-25. doi: 10.1016/j.lungcan.2013.02.007. Epub 2013 Mar 20.

PMID:
23522488
49.

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators.

Ann Oncol. 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15.

PMID:
23161898
50.

Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.

Scagliotti GV, Ilaria R Jr, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C.

J Thorac Oncol. 2012 Jun;7(6):1053-7. doi: 10.1097/JTO.0b013e3182519d79.

Supplemental Content

Loading ...
Support Center